A Phase 2 interventional study of Adalimumab in Uveitis and Non-Infectious Uveitis, sponsored by American University of Beirut Medical Center. Terminated at 1 site in Lebanon. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by American University of Beirut Medical Center · Phase 2, Interventional, and Treatment
The trial was terminated prematurely due to factors unrelated to safety or efficacy outcomes. A severe nationwide shortage of adalimumab compounded by a financial crisis prevented the study from reaching its planned enrollment of 32 patients.
The objective of this study is to compare and evaluate the efficacy of subcutaneous (40mg) adalimumab biweekly injections to intravitreal adalimumab (1.5 mg/ 0.03 mL) administration, given at zero, 2 weeks then every four weeks, in subjects with active non-infectious intermediate-, posterior-, or pan-uveitis.
Subject groups:
32 subjects will be enrolled in this study, 16 in each arm. They will be randomized to receive either 1.5 mg/ 0.03 mL of adalimumab by intravitreal injection or 40 mg of adalimumab subcutaneously at their first treatment visit and at the 2 weeks visit if eligible for a repeat injection. Follow up will be every 2 days the first week then one week later and after that every 4-week intervals for total of 26 weeks.
Intervention Details:
Pre-treatment work up
Patients will undergo a comprehensive eye exam:
Post-injection follow-up
299 studies on the registry are indexed under Uveitis; 32 are open to participants now.
This study's enrollment of 23 is below the median of 30 across 175 interventional studies indexed under Uveitis.
Browse Uveitis studies →American University of Beirut Medical Center is the lead sponsor of 158 studies on the registry; 24 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject must have active disease at baseline as defined by the presence of at least 1 of the following parameters in at least one eye despite at least 2 weeks of prednisone ≥ 10 mg/day (or oral equivalent):
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intravitreal injection of 1.5mg/0.03ml adalimumab given at zero, 2 weeks, and then every 4 weeks.
Drug: Adalimumab
Subcutaneous injection of 40 mg adalimumab (Humira) given every 2 weeks.
Drug: Adalimumab
Vitreous Haze
Change in Vitreous Haze grade in each eye \[National Eye Institute (NEI)/ Standardization of Uveitis Nomenclature (SUN) criteria\]
Time frame: 26 Weeks
Anterior Chamber Cells
Change in Anterior Chamber (AC) cell grade in each eye.
Time frame: 26 Weeks
Visual Acuity
Change in ETDRS letters and logarithm of the minimum angle of resolution (log MAR) best-corrected visual acuity (BCVA) in each eye.
Time frame: 26 Weeks
Macular Edema
Change in central retinal thickness on Optical Coherence Tomography (OCT).
Time frame: 26 Weeks
Angiography Score
Change in fluorescein angiography score
Time frame: 26 Weeks
Steroids Tapering
If the patient is initially on steroids (pre-enrolment); Success in tapering steroid dose as a response to the protocol.
Time frame: 26 Weeks
Plan to share: No
Ran from Feb 2016 to primary completion in Jan 2022, 71 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: primary completion Dec 2025 → Jan 2022 and completion Feb 2026 → Jan 2022.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
The trial was terminated prematurely due to factors unrelated to safety or efficacy outcomes. A severe nationwide shortage of adalimumab compounded by a financial crisis prevented the study from reaching its planned enrollment of 32 patients.
The trial was terminated prematurely due to factors unrelated to safety or efficacy outcomes. A severe nationwide shortage of adalimumab compounded by a financial crisis prevented the study from reaching its planned enrollment of 32 patients.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adalimumab
American University of Beirut Medical Center →